EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report

Bach Ardalan iD, Jose Ignacio Azqueta, Jonathan England, Tiffany Alyssa Eatz iD

Molecular Case Studies · 2021-10 · 7 (5) · a006108

DOI: 10.1101/mcs.a006108 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Case Studies, online erschienen am 19.10.2021. Verfasst von Bach Ardalan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida 33136, USA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This is the first case report of a 60-yr-old female who underwent therapy for metastatic pancreatic cancer with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). Upon the progression of her disease, she was switched to gemcitabine and nab-paclitaxel. Per genomic sequencing, her tumor was found to be a KRAS wild-type and BRAF V600E mutation, which then warranted treatment with the MEK1 and MEK2 inhibitor, cobimetinib. The patient has achieved a complete response (CR) to a combination of gemcitabine, nab-paclitaxel, and cobimetinib. It has been 16 mo since the start of the treatment, and the patient continues to demonstrate a complete durable response both serologically and radiologically.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)

Stichwörter der Autor:innen

neoplasm of the pancreas

Substanzen

KRAS protein, humanBRAF protein, humanProto-Oncogene Proteins B-rafMitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida 33136, USA.

ORCID-Profile: Bach Ardalan, Tiffany Alyssa Eatz

Zitieren

APA

Ardalan, B., Azqueta, J. I., England, J., & Eatz, T. A. (2021). Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report. Molecular Case Studies, 7(5), a006108. https://doi.org/10.1101/mcs.a006108

Vancouver

Ardalan B, Azqueta JI, England J, Eatz TA. Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report. Molecular Case Studies. 2021;7(5):a006108. doi:10.1101/mcs.a006108

BibTeX
@article{Ardalan2021,
  author = {Ardalan, Bach and Azqueta, Jose Ignacio and England, Jonathan and Eatz, Tiffany Alyssa},
  title = {Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report},
  journal = {Molecular Case Studies},
  year = {2021},
  volume = {7},
  number = {5},
  pages = {a006108},
  doi = {10.1101/mcs.a006108}
}
Kostenlos starten →